CoChat

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Open access
McInnes, Iain B, Sieper, Joachim, Braun, Jürgen, Emery, Paul, van der Heijde, Désirée, Isaacs, John D, Dahmen, Georg, Wollenhaupt, Jürgen, Schulze-Koops, Hendrik, Kogan, Joseph, Ma, Shenglin, Schumacher, Martin M, Bertolino, Arthur P, Hueber, Wolfgang, Tak, Paul P · 2014 · Annals of the Rheumatic Diseases

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Objective To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA).Methods 42 patients with active PsA fulfilling ClASsification for Psoriatic ARthritis (CASPAR) criteria were randomly assigned (2:1) to receive two intravenous secukinumab doses (10 mg/kg; n=28) or placebo (n=14) 3 weeks apart. The primary endpoint was the proportion of American College of Rheumatology (ACR) 20 responses at week 6 for secukinumab versus placebo (one-sided p<0.1).Results Primary endpoint: ACR20 responses at week 6 were 39% (9/23) for secukinumab versus 23% (3/13) for placebo (p=0.27). ACR20 responses were greater with secukinumab versus placebo at week 12 (39% (9/23) vs 15% (2/13), p=0.13) and week 24 (43% (10/23) vs 18% (2/11), p= 0.14). At week 6, 'good' European League Against Rheumatism response was seen in 21.7% (5/23) secukinumab versus 9.1% (1/11) placebo patients. Compared with placebo at week 6, significant reductions were observed among secukinumab recipients for C reactive protein (p=0.039), erythrocyte sedimentation rate (p=0.038), Health Assessment Questionnaire Disability Index (p=0.002) and Short Form Health Survey (SF-36; p=0.030) scores. The overall adverse event (AE) frequency was comparable between secukinumab (26 (93%)) and placebo (11 (79%)) recipients. Six serious AEs (SAEs) were reported in four secukinumab patients and one SAE in one placebo patient.Conclusions Although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit. Secukinumab exhibited satisfactory safety. Larger clinical trials of secukinumab in PsA are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2012-202646

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 2

  1. Raychaudhuri, 2012, IL-17 receptor and its functional significance in psoriatic arthritis, Mol Cell Biochem, 359, 419, 10.1007/s11010-011-1036-6 · DOI · Paper page
  2. Baeten, 2011, The anti-IL-17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis, Ann Rheum Dis, 70, 127

Cited by

See all 343

Metadata

Authors
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., Ma, S., Schumacher, M. M., Bertolino, A. P., Hueber, W., & Tak, P. P.
Affiliations
  • University of Glasgow (GB)
  • Charité – Universitätsmedizin Berlin (DE)
  • Rheumazentrum Ruhrgebiet (DE)
  • University of Leeds (GB)
  • Newcastle University (GB)
  • Schön Klinik Hamburg Eilbek (DE)
  • Novartis (Switzerland) (CH)
  • Novartis (China) (CN)
  • GlaxoSmithKline (United Kingdom) (GB)
Corresponding author
Hueber, Wolfgang
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2014-02
Volume
73
Issue
2
Pages
349-356
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2151280501
Cited by
343
References
41
Citations by year
2026: 4 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 16 · 2021: 23 · 2020: 14 · 2019: 22 · 2018: 31 · 2017: 34 · 2016: 42 · 2015: 51 · 2014: 62
FWCI
48.39
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Annals of the Rheumatic Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • The Novartis Repository (Novartis) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • National Institute for Health and Care Research (NF-SI-0508-10299)
  • Versus Arthritis (18475)
Topics
  • Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
secukinumab, psoriatic arthritis, IL-17A, anti-IL-17A monoclonal antibody, biologic therapy, ACR20 response, disease activity, adverse events, treatment safety, CASPAR classification criteria, health-related quality of life, C-reactive protein, erythrocyte sedimentation rate
MeSH terms
Adult, Antibodies, Monoclonal, Blood Sedimentation, C-Reactive Protein, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Severity of Illness Index, Biomarkers, Arthritis, Psoriatic, Treatment Outcome, Antirheumatic Agents, Interleukin-17, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2012-202646
The paper
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., Ma, S., Schumacher, M. M., Bertolino, A. P., Hueber, W., & Tak, P. P. (2014). Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-202646

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.